Picture of Benchmark Holdings logo

BMK — Benchmark Holdings News Story

0.000.00%
gb flag iconLast trade - 00:00
Consumer DefensivesAdventurousSmall CapNeutral

Second Quarter and Interim Results

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240522:nRSV3736Pa&default-theme=true

RNS Number : 3736P  Benchmark Holdings PLC  22 May 2024

Information within this announcement is deemed by the Company to constitute
inside information under the Market Abuse Regulations (EU) No. 596/2014 and
Article 7 of the UK version of EU Regulation 596/2014 which forms part
of UK law by virtue of the European Union (Withdrawal) Act 2018.

 

22 May 2024

 

Benchmark Holdings plc

 

("Benchmark", the "Company" or the "Group")

 

Second Quarter and Half Year results for the six months ended 31 March 2024

 

Positive quarterly momentum maintained and well on track to meet full year
management's expectations

 

Benchmark (LSE: BMK), the aquaculture biotechnology company, announces its
unaudited interim results for the six months ended 31 March 2024 (the "Period"
or "H1 FY24"). The Company also announces its unaudited results for the three
months ended 31 March 2024 ("Q2 FY24") in compliance with the terms of its
unsecured Green bond.

Financial Highlights

·    Q2 FY24 positive momentum in Genetics and Advanced Nutrition
partially offset by Health and forex headwinds

o  Q2 FY24 revenues of £39.8m were 10% below Q2 FY23 (-3% CER) driven by a
strong performance in Genetics and Advanced Nutrition, offset by Health

§ Genetics revenues were £13.2m (Q2 FY23: £12.9m) up 7% CER reflecting a
solid performance in the core business and good progress in our growth
vectors, particularly Chile

§ Advanced Nutrition revenues were £21.1m (Q2 FY23: £22.6m) up 3% CER
reflecting the success of our strategy to adapt to difficult shrimp markets

§ Health revenues of £5.4m (Q2 FY23: £8.7m) were down 35% CER; focus
remains on transition to new business model for Ectosan®Vet and CleanTreat®

o  9% CER increase in Adjusted EBITDA excluding fair value movement in
biological assets to £9.9m (Q2 FY23: £9.9m)

o  Adjusted EBITDA margin excluding fair value movement in biological assets
of 25% (Q2 FY23: 22%) in line with the Group's medium-term target

§ Genetics Adjusted EBITDA excluding fair value movement of £3.1m was 42%
above Q2 FY23 (+50% CER) due to higher profit from the Genetics joint venture
and higher egg revenues. The Adjusted EBITDA excluding fair value movement
margin was 24% (Q2 FY23: 17%)

§ Advanced Nutrition Adjusted EBITDA of £5.3m was down 14% (-3% CER) with
effective cost control offsetting reduced revenue. The Adjusted EBITDA margin
was 25%; (Q2 FY23: 27%)

§ Health Adjusted EBITDA of £1.6m (Q2 FY23: £2.6m) and Adjusted EBITDA
margin of 30% reflecting efforts to manage costs (Q2 FY23: 30%)

o  Adjusted operating profit excluding fair value movements was £5.9m, 24%
above the prior year

o  Operating profit was marginally below the prior year at £0.6m (Q2 FY23:
£0.7m)

o  Increase in net operating cash inflow to £3.6m (Q2 FY23: £1.4m)

·    H1 FY24 results underpinned by strong Q2 performance, supporting
positive outlook for the full year

o  H1 FY24 revenues of £80.2m were 19% below a strong H1 FY23 (-12% CER)
which benefited from supply constraints in the salmon egg market

§ Genetics revenues were £28.4m (H1 FY23: £34.3m) down 11% CER reflecting a
normalised level against H1 FY23 which benefitted from supply constraints in
the salmon egg market

§ Advanced Nutrition revenues were £40.4m (H1 FY23: £45.3m), down 2% CER
representing a strong performance in challenging shrimp markets

§ Health revenues of £11.5m (H1 FY23: £19.1m) were down 37% CER; reduced
Ectosan®Vet and CleanTreat® capacity in the period as we transition to a new
business model

o  Adjusted EBITDA excluding fair value movement in biological assets was
£17.3m, 23% below a strong H1 FY23 (-15% CER)

o  Group operating costs in H1 FY24 were £20.4m, 14% below H1 FY23 with a
reduction across all business areas despite a high inflation environment

o  Adjusted EBITDA margin excluding fair value movement in biological assets
was 22% (H1 FY23: 23%) with strong margins in Advanced Nutrition (24%) and
Genetics (23%) offset by Health (19%)

o  Operating loss was £3.7m (H1 FY23: profit of £1.0m) primarily due to
lower revenues in the period offset by continued cost control

 

·    Cash, liquidity and net debt:

o  Cash of £24.1m and liquidity (cash and available facility) of £41.3m at
20 May 2024

o  Net debt excluding lease liabilities of £56.8m at 31 March 2024 (31 March
2023: £44.5m,

 30 September 2023: £45.6m)

H1 FY24 Operational Highlights

·    Genetics - wide ranging progress

o  Excellent progress in Chile with new customer wins, establishing
foundation for future growth

o  Launch of a new product portfolio in salmon genetics aligned with our
strategy to invest in R&D to further enhance our customer value
proposition and our competitive position

o  Successful launch of genotyping product portfolio; contracted customer
projects commenced

o  Successful integration of shrimp activities with Advanced Nutrition
generating commercial opportunities while we continue the work to develop
local adapted strains

o  Significant progress in key innovation areas - complex gill disease
project bolstered by a new partnership funded by the Biotechnology and
Biological Sciences Research Council in the UK

 

·    Advanced Nutrition - well positioned for recovery

o  The strategy and mitigating actions taken by management in response to
challenging shrimp markets including the continuous development of our product
portfolio, the establishment of new routes to market and the implementation of
operational efficiencies are delivering positive results

o  Green shoots of recovery in the shrimp market translating into demand for
the Group's hatchery portfolio as the industry prepares to increase production

o  Well positioned for market recovery

 

·     Health - progress with development of new business model

o  Further progress made towards development of new business model for
Ectosan® Vet and CleanTreat® aimed at reducing infrastructure costs.
  Design of the wellboat configuration completed in partnership with
wellboat equipment provider MMC and wellboat designer SALT

o  Existing infrastructure being streamlined, rightsizing it for the new
business model

o  Strong sales of Salmosan® Vet reflecting successful lifecycle management
and strength of the Group's sea lice solution portfolio

Current trading and outlook

The Company is trading in line with management's expectations for the full
year. There is good visibility of revenue in Genetics including excellent
progress in Chile, and there have been no operational or financial
consequences from the infectious salmon anaemia (ISA) incident reported in
February this year. In Advanced Nutrition, there is continuing strong
performance in soft markets albeit with some green shoots and the business is
well positioned for market recovery. In Health, our focus remains on the
transition to the new business model for Ectosan® Vet and CleanTreat®. We
will continue to manage costs and reduce our capital exposure, taking the
second CleanTreat® unit out ahead of the low season for sea lice
treatments.  Our established sea lice treatment Salmosan® Vet is performing
well into the second half of the year.

Strategic review

In January 2024, the Company announced that the Board had unanimously decided
to undertake a formal review of the Company's strategic options including a
potential formal sale process. This process remains ongoing and further
updates will be provided as appropriate.

Financial Summary

 £m                                                                        Q2 FY23  % CER                         % CER

                                                                 Q2 FY24            Q2 FY24   H1 FY24   H1 FY23   H1 FY24
 Revenue                                                         39.8      44.2     -3%       80.2      98.7      -12%

                                                                           -10%                         -19%
 Adjusted
 Adjusted EBITDA(1)                                              10.1      11.3     -1%       16.8      22.6      -18%

                                                                           -10%                         -26%
 Adjusted EBITDA excl. bio asset fair value movements            9.9       9.9      +9%       17.3      22.4      -15%

                                                                           0%                           -23%
 Adjusted Operating profit(2)                                    6.2       6.2      +15%      6.0       12.4      -40%

                                                                           0%                           -51%
 Adjusted Operating profit excl. bio asset fair value movements  5.9       4.8      +42%      6.5       12.1      -34%

                                                                           +24%                         -46%
 Statutory
 Operating profit/(loss)                                         0.6       0.7                (3.7)     1.0

                                                                           -6%                          -468%
 Loss before tax                                                 (0.7)     (1.7)              (7.9)     (1.2)

                                                                           +61%                         -564%
 Basic loss per share (p)                                        (0.18)    (0.40)             (1.21)    (0.57)
 Net debt(3)                                                     (72.7)    (66.3)             (72.7)    (66.3)
 Net debt(3) excluding lease liabilities                         (56.8)    (44.5)             (56.8)    (44.5)

 

 

*Constant exchange rate (CER) figures derived by retranslating current year
figures using previous year's foreign exchange rates

(1) Adjusted EBITDA is EBITDA (earnings before interest, tax, depreciation and
amortisation and impairment), before exceptional items including acquisition
related expenditure

(2) Adjusted Operating Profit is operating loss before exceptional items
including acquisition related items and amortisation of intangible assets
excluding development costs

(3) Net debt is cash and cash equivalents less loans and borrowings

Business Area summary

 £m                                                                                              % CER*                        %CER*

                                                                             Q2 FY24   Q2 FY23   Q2 FY24   H1 FY24   H1 FY23   H1 FY24
 Revenue
 Advanced Nutrition                                                          21.1      22.6      +3%       40.4      45.3      -2%

                                                                                       -7%                           -11%
 Genetics                                                                    13.2      12.9      +7%       28.4      34.3      -11%

                                                                                       +2%                           -17%
 Health                                                                      5.4       8.7       -35%      11.5      19.1      -37%

                                                                                       -38%                          -40%
 Adjusted EBITDA(1)
 Advanced Nutrition                                                          5.3       6.2       -3%       9.9       11.5      -5%

                                                                                       -14%                          -14%
 Adjusted EBITDA Margin (%)                                                  25%       27%                 24%       25%
 Genetics                                                                    3.4       3.6       1%        5.9       6.5       -2%

                                                                                       -5%                           -10%
 - Net of fair value movement in biological assets                           3.1       2.2       +50%      6.4       6.3       +12%

                                                                                       +42%                          +2%
 Adjusted EBITDA Margin (%) excl. fair value movements in biological assets  24%       17%                 23%       18%
 Health                                                                      1.6       2.6       -34%      2.2       6.6       -65%

                                                                                       -37%                          -67%
 Adjusted EBITDA Margin (%)                                                  30%       30%                 19%       35%

*Constant exchange rate (CER) figures derived by retranslating current year
figures using previous year's foreign exchange rates

(1) Adjusted EBITDA is EBITDA (earnings before interest, tax, depreciation and
amortisation and impairment), before exceptional items including acquisition
related expenditure

 

 

Trond Williksen, CEO, commented:

 

"I am pleased with the Company's performance in the second quarter, and the
first half as a whole, which demonstrated good momentum in the business
supporting our positive outlook. We have delivered strong trading in our
established business areas, have made excellent progress in Chile, one of our
key growth vectors, and made significant progress in our innovation programme
where our recent investment to strengthen our innovation capabilities is
bearing fruit. We remain focused on the transition to a new business model for
Ectosan® Vet and CleanTreat® which will strengthen our sea lice solutions
portfolio and deliver a much needed alternative to our customers.

 

"With our unique platform of mission critical specialised solutions in areas
where we hold market leading positions we are strongly positioned to continue
to deliver growth and to build sustainable shareholder value."

 

Presentation for analysts and institutional investors at 8.00 UK (9.00 CET)

 

Trond Williksen, Chief Executive Officer and Septima Maguire, Chief Financial
Officer will host a presentation for analysts and institutional investors on
the day at 08.00 UK time (9.00 CET).

 

The presentation will be held in person at Haakon Vlls Gate 2, Oslo, Norway.
To register your interest, please contact benchmark@mhpgroup.com
(mailto:benchmark@mhpgroup.com)

 

A live webcast of the presentation will be available for analysts and
investors to join remotely at the following link:
https://channel.royalcast.com/landingpage/hegnarmedia/20240522_1/
(https://channel.royalcast.com/landingpage/hegnarmedia/20240522_1/)

 

Equity Development webcast for retail investors at 12:30pm UK time

 

Trond Williksen, Chief Executive Officer and Septima Maguire, Chief Financial
Officer will host a second webcast for retail investors and wealth managers at
12.30pm UK time. The webcast is open to all existing and potential
shareholders.

 

To register please visit:
https://www.equitydevelopment.co.uk/news-and-events/benchmark-investor-presentation-22may2024
(https://www.equitydevelopment.co.uk/news-and-events/benchmark-investor-presentation-22may2024)

 

 

Enquiries

 

 For further information, please contact:
 Benchmark Holdings plc                         benchmark@mphgroup.com (mailto:benchmark@mphgroup.com)
 Trond Williksen, CEO
 Septima Maguire, CFO
 Ivonne Cantu, Investor Relations

 Numis (Broker and NOMAD)                       Tel:  +44 20 7260 1000
 Freddie Barnfield, Duncan Monteith, Sher Shah

 MHP Group                                      Tel:  +4420 3128 8100/ +44 7884 494112

Katie Hunt, Reg Hoare
 
 
 benchmark@mhpgroup.com (mailto:benchmark@mhpgroup.com)

 

About Benchmark

Benchmark is a market leading aquaculture biotechnology company. Benchmark's
mission is to drive sustainability in aquaculture by delivering products and
solutions in genetics, advanced nutrition and health which improve yield,
growth, animal health and welfare.

Through a global footprint in 26 countries and a broad portfolio of products
and solutions, Benchmark addresses the major aquaculture species in all the
major aquaculture regions around the world. Find out more at
www.benchmarkplc.com (http://www.benchmarkplc.com)

 

Management Report

 

Q2 FY24 commentary

 

The Group delivered a strong performance in Q2 FY24 with Genetics and Advanced
Nutrition performing strongly against a backdrop of difficult conditions in
the shrimp markets, and progress made in Health towards a new business model
for Ectosan® Vet and CleanTreat®.  Group revenue was £39.8m, 10% below a
strong Q2 FY23

(-3% CER).  Adjusted EBITDA excluding fair value movement in biological
assets was £9.9m, in line with Q2 FY23 despite strong forex headwinds, and
ahead +9% at constant exchange rate. The Adjusted EBITDA margin excluding fair
value movement in biological assets of 25% was in line with the Group's
medium-term target (Q2 2023: 22%).

 

By business area, Genetics reported Q2 FY24 revenues of £13.2m, 2% above Q2
FY23 (+7% CER) driven by higher egg revenues (+2%) as well as higher harvest
income (+70%) and genetic services revenues (+17%), partially offset by lower
revenues in ancillary products. Adjusted EBITDA excluding fair value movements
in biological assets was £3.1m, up 42% on the prior year (Q2 FY23: £2.2m)
reflecting higher revenues as well as higher profits from the Genetics joint
venture in the period of £0.7m (Q2 FY23: nil).  The Adjusted EBITDA margin
excluding fair value movements was 24% (Q2 FY23: 17%) reflecting higher profit
from the joint venture and higher harvest income. There was excellent progress
in Chile, a key growth vector for the Group with an increasing number of
customers, building our market position and achieving operational
profitability. In shrimp, the integration of our shrimp genetics commercial
activities with Advanced Nutrition to leverage our commercial capabilities is
creating new opportunities as we continue the development of local adapted
strains. Shrimp sales were £0.5m in the period 31% above the prior year.
During the period we successfully launched a new genotyping product portfolio
and there are a number of contracted customer projects already underway which
underpin future revenue.  Innovation is a key component of our Genetics
strategy and significant progress was made in our key R&D projects in the
period. This included a new partnership for our complex gill disease project,
which was bolstered by a new important partnership with funding from the
Biotechnology and Biological Sciences Research Council in the UK.

 

Advanced Nutrition delivered Q2 FY24 revenues of £21.1m, 7% below Q2 FY23
largely due to forex impact (+3% CER) but 10% above Q1 FY24 showing good
quarterly momentum. Q2 FY24 Adjusted EBITDA was £5.3m (Q2 FY23: £6.2m) with
the impact of the lower sales partially offset by efficient cost control. The
Adjusted EBITDA margin was 25% (Q2 FY23: 27%).  While the shrimp markets
remain soft, there are green shoots of recovery which translated into
improving demand for our hatchery portfolio in the period as the industry
prepares to increase production as further signs of recovery emerge.

 

In Health, Q2 FY24 revenues were £5.4m, 38% below Q2 FY23 (-35% CER), and
Adjusted EBITDA was £1.6m (Q2 FY23: £2.6m). Sales of Salmosan® Vet were
strong reflecting successful lifecycle management and the strength of the
Group's sea lice solution portfolio. Our focus remains on the development of
alternative operating models for Ectosan® Vet and CleanTreat® including
barge and wellboat configurations. As part of this transition we are
streamlining the infrastructure and organisation in Health, rightsizing for
the new business model which will result in cost savings. Early in the quarter
we took one of the two platform supply vessels (PSV) carrying the CleanTreat®
systems out of service and we have streamlined the rest of the organisation
accordingly. The wellboat configuration represents the long-term solution,
with the CleanTreat® systems integrated into future wellboats owned and
operated by customers or service providers. We have completed the design for
the wellboat configuration in partnership with leading wellboat equipment
provider, MMC, and leading wellboat designer SALT, and together we are now
promoting the solution as part of the offering of new wellboats in the market.

 

Group operating costs were £9.9m, 19% below prior year (Q2 FY23: £12.2m) as
focus continues on cost control across the Group, including streamlining the
infrastructure of the Health business area, a programme of operational
efficiencies and the ongoing integration of our activities around species.
 R&D expenses of £1.5m were marginally above the prior year (Q2 FY23:
£1.4m) and represented 4% of Group revenues (Q2 FY23: 3%). Exceptional costs
in the quarter, mainly related to the ongoing strategic review, were £2.0m
(Q2 FY23: £1.7m related to costs in preparation for an Oslo listing).
Depreciation and amortisation was £7.5m (Q2 FY23: £8.9m) with the reduction
mainly relating to right of use assets in Health, leading to a Group operating
profit of £0.6m (Q2 FY23: £0.7m). Adjusted operating profit excluding fair
value movement in biological assets was £5.9m, 24% (+42% CER) ahead of the
prior year (Q2 FY23: £4.8m).

 

Net finance costs of £1.3m for the quarter were £1.1m lower than the same
period last year (Q2 FY23: £2.4m), mainly due to net forex gains in the
period of £1.3m (Q2 FY23: loss of £0.7m) partially offset by higher interest
costs.  Loss before tax for the quarter was £0.7m (Q2 FY23: £1.7m).

 

The tax charge for the quarter was £0.5m (Q2 FY23: £0.7m) resulting in loss
after tax of £1.1m (Q2 FY23: £2.4m).

 

The Group reported a net operating cash outflow of £3.6m after an increase in
working capital of £1.9m (Q2 FY23: £3.4m) and tax payments of £2.5m (Q2
FY23: £2.6m). Net cash outflow from investing activities was £0.7m (Q2 FY23:
£1.3m) of which capex was £0.9m (Q2 FY23: £1.6m) offset by proceeds from
sale of fixed assets, the reduction comes as the significant investment
programme to support the Group's growth plans is now complete.

Net cash outflow from financing activities was £5.9m (Q2 FY23: £3.4m).
Current period relates to payments for interest and lease and borrowings
payments, whereas prior year included increase in bank borrowings of £9.2m
offset by £8.0m for acquisition of minority interest in Iceland.

 

Half year commentary

 

Revenues in H1 FY24 were £80.2m, 19% below a strong H1 FY23 (-12% CER) but
13% above the H2 FY23 period showing positive sequential progress against a
backdrop of difficult conditions in the shrimp markets. Adjusted EBITDA
excluding fair value movements from biological assets was £17.3m down 23%
(-15% CER). The Adjusted EBITDA margin excluding fair value movement was
marginally below at 22% (H1 FY23: 23%) with a higher contribution from joint
venture profit offsetting a slightly lower gross profit margin of 49% (H1
FY23: 50%).

 

By business area, Advanced Nutrition delivered a strong performance against
challenging markets, with green shoots of recovery in Q2 FY24. First half
revenues were £40.4m, 11% below H1 FY23 impacted by forex headwinds (-2% CER)
but 22% ahead of H2 FY23 showing sequential progression partially reflecting
signs of market improvement as mentioned above. H1 FY24 Adjusted EBITDA was
£9.9m, 14% below H1 FY23 (-5% CER) resulting in Adjusted EBTIDA margin of 24%
(H1 FY23: 25%).  While conditions in the shrimp market remained difficult,
signs of recovery give us optimism and we are confident that the business is
very well positioned to benefit from market recovery, with the strategy and
mitigating actions implemented over recent periods including development of
our product portfolio and technologies, new routes to market and operational
efficiencies delivering results.

 

Genetics performed well against a comparatively strong H1 FY23.  Revenues of
£28.4m were 17% below H1 FY23 and were impacted by adverse forex (CER -11%).
The drop in revenues was driven by a 20% reduction in salmon egg revenues
against H1 FY23, which benefitted from supply constraints in the salmon egg
market and lower revenues from ancillary products and other income, partially
offset by a 12% increase in harvest revenues and a 9% increase in revenues
from Genetic Services. Revenues from shrimp genetics were marginally down.
Adjusted EBITDA excluding fair value movement was £6.4m 2% above the prior
year (+12% CER) resulting in a lift in Adjusted EBITDA margin excluding fair
value movement to 23% (H1 FY23: 18%).

 

In Health, we continue our effort to transition to a new infrastructure and
business model for Ectosan® Vet and CleanTreat® including streamlining our
infrastructure and reducing capacity to manage costs during the transition
period. Revenues in H1 FY24 were £11.5m 40% below the prior year (-37% CER)
driven by a drop in Ectosan® Vet and CleanTreat® while revenues from
Salmosan® Vet were 8% down as a result of a change in geographic mix with an
increase in volume offset by lower average price.

 

Group operating costs in H1 FY24 were £20.4m, 14% below H1 FY23 with a
reduction across all business areas despite a high inflation environment. This
is the result of well embedded cost control across the Group, a programme of
operational efficiencies and the ongoing integration of our activities around
species. R&D expenses were £3.1m (H1 FY23: £3.0m) and total R&D
investment including capitalised development costs was £3.2m, in line with
the prior year (H1 FY23: £3.2m). Depreciation and amortisation were £18.1m
(H1 FY23: £18.9m) with the reduction mainly related to right of use assets
in the Health business area.

 

The Group reported an operating loss of £3.7m (H1 FY23: £1.0m profit) as a
result of lower revenues partially offset by a reduction in operating costs
and increased profit from joint ventures. Adjusted operating profit excluding
fair value movements from biological assets was £6.5m, 46% below H1 FY23
(-34% CER) but significantly ahead (+151%) of the most recent six month
period.

 

Net finance costs for H1 FY24 were £4.1m (H1 FY23: £2.2m).  Interest costs
were higher due to higher borrowings during the current year, and the
remainder of the increase is the result of income from ineffectiveness in
hedge accounting in the prior year offset by differences in foreign exchange
gains and losses year on year.

 

Loss before tax in H1 FY24 was £7.9m (H1 FY23: £1.2m). This included the
impact of significant exceptional costs in the period of £2.5m (H1 FY23:
£2.7m), largely related to the ongoing strategic review and restructuring
costs associated with the integration of our shrimp genetics activities and
other operational efficiency initiatives, while those in the prior period were
primarily concerned with preparation for a listing of the Group in Oslo.

 

Total tax charge in H1 FY24 was £0.9m (H1 FY23: £1.5m) with a small
reduction (+£0.2m) in current tax charges in the territories for which no
loss relief is available, together with a higher deferred tax credit (+£0.4m)
from the reversal of temporary differences. Loss after tax was £8.8m (H1
FY23: £2.7m loss).

 

The Group reported a net operating cash outflow of £2.0m after an increase in
working capital of £12.8m (H1 FY23: £4.2m) and tax payments of £3.7m (H1
FY23: £4.1m). The increase in working capital is somewhat seasonal, but the
larger increase this year is due to higher receivables resulting from
increased harvest income and timing of egg sales in Genetics, a reduction in
payables in Advanced Nutrition due to different timing, and the utilisation of
the demobilisation provision in Health following decommissioning of one of the
vessels. Net cash outflow from investing activities was £1.5m (H1 FY23:
£3.4m) as the significant investment programme to support the Group's growth
plans is now complete.  The majority of the outflow in the period relates to
maintenance capex in Genetics.

 

Net cash outflow from financing activities was £11.4m (H1 FY23: £1.2m).
 Interest payments in the period were £4.5m (H1 FY23: £4.1m) and lease
payments were £5.4m (H1 FY23: £4.7m).  Additionally, H1 FY23 included an
equity raise of (net) £11.4m, net proceeds from debt refinancing of £4.2m,
and payments to acquire the minority interests in Benchmark Genetics Iceland
of £8.0m.  The cash position at 31 March 2024 was £20.8m (H1 FY23: £38.6m;
FY23: £36.5m), and net debt including lease liabilities was £72.7m (H1 FY23:
£66.3m; FY23: £65.5m).

 

Outlook

 

The Company is trading in line with management's expectations for the full
year. There is good visibility of revenue in Genetics including excellent
progress in Chile and no operational or financial consequences from the ISA
incident reported in February this year. In Advanced Nutrition there is
continuing strong performance in soft markets albeit with some green shoots,
and the business is well positioned for market recovery. In Health our focus
remains on the transition to the new business model for Ectosan® Vet and
CleanTreat®. We will continue to manage costs and reduce our capital
exposure, taking the second CleanTreat® unit out of service ahead of the low
season for sea lice treatments.  Our established sea lice treatment
Salmosan® Vet is performing well into the second half of the year.

Benchmark Holdings plc

 

Consolidated Income Statement for the period ended 31 March 2024

 

 

 

 

 All figures in £000's                                                Notes  Q2 2024       Q2 2023       YTD Q2 2024   YTD Q2 2023   FY 2023

(unaudited)
Restated*
(unaudited)
Restated*
(audited)

(unaudited)
(unaudited)
 Revenue                                                              4      39,751        44,237        80,224        98,659        169,476
 Cost of sales                                                               (18,866)      (19,313)      (40,976)      (49,337)      (82,726)
 Gross profit                                                                20,885        24,924        39,248        49,322        86,750
 Research and development costs                                              (1,542)       (1,434)       (3,059)       (2,985)       (6,069)
 Other operating costs                                                       (9,862)       (12,203)      (20,352)      (23,771)      (45,157)
 Share of profit/(loss) of equity-accounted investees, net of tax            667           -             985           56            (32)
 Adjusted EBITDA²                                                            10,148        11,287        16,822        22,622        35,492
 Exceptional - restructuring, acquisition and disposal related items  6      (1,962)       (1,716)       (2,479)       (2,688)       (3,904)
 EBITDA¹                                                                     8,186         9,571         14,343        19,934        31,588
 Depreciation and impairment                                                 (3,318)       (4,475)       (9,567)       (9,014)       (18,409)
 Amortisation and impairment                                                 (4,221)       (4,410)       (8,489)       (9,912)       (18,495)
 Operating (loss)/profit                                                     647           686           (3,713)       1,008         (5,316)
 Finance cost                                                         7      (3,201)       (3,214)       (6,497)       (10,335)      (15,048)
 Finance income                                                       7      1,884         791           2,349         8,143         7,670
 Loss before taxation                                                        (670)         (1,737)       (7,861)       (1,184)       (12,694)
 Tax on loss                                                          8      (477)         (704)         (910)         (1,483)       (3,365)
 Loss from continuing operations                                             (1,147)       (2,441)       (8,771)       (2,667)       (16,059)
 Discontinued operations
 Loss from discontinued operations, net of tax                        5      -             (279)         -             (732)         (5,505)
                                                                             (1,147)       (2,720)       (8,771)       (3,399)       (21,564)
 Loss for the year attributable to:
 - Owners of the parent                                                      (1,321)       (2,858)       (8,948)       (4,141)       (23,146)
 - Non-controlling interest                                                  174           138           177           742           1,582
                                                                             (1,147)       (2,720)       (8,771)       (3,399)       (21,564)

 Earnings per share
 Basic loss per share (pence)                                         9      (0.18)        (0.40)        (1.21)        (0.57)        (3.16)
 Diluted loss per share (pence)                                       9      (0.18)        (0.40)        (1.21)        (0.57)        (3.16)
 Earnings per share - continuing operations
 Basic loss per share (pence)                                         9      (0.18)        (0.36)        (1.21)        (0.47)        (2.41)
 Diluted loss per share (pence)                                       9      (0.18)        (0.36)        (1.21)        (0.47)        (2.41)

 Adjusted EBITDA from continuing operations                                  10,148        11,287        16,822        22,622        35,492
 Adjusted EBITDA from discontinued operations                         5      -             (194)         -             (562)         (1,254)
 Total Adjusted EBITDA                                                       10,148        11,093        16,822        22,060        34,238

 

 

1 EBITDA - Earnings before interest, tax, depreciation, amortisation, and
impairment

2 Adjusted EBITDA - EBITDA before exceptional items including acquisition
related items

* Q2 2023 numbers have been restated to reflect certain operations of the
Group that have been classified as discontinued operations    during the
period in line with IFRS 5. (See Note 5).

 

Benchmark Holdings plc

 

Consolidated Statement of Comprehensive Income for the period ended 31 March
2024

 

 

 

 All figures in £000's                                                                                       Q2 2024       Q2 2023       YTD Q2 2024   YTD Q2 2023   FY 2023

(unaudited)
Restated
(unaudited)
Restated
(audited)

(unaudited)
(unaudited)

 Loss for the period                                                                                         (1,147)       (2,720)       (8,771)       (3,399)       (21,564)
 Other comprehensive income
 Items that are or may be reclassified subsequently to profit or loss
 Foreign exchange translation differences                                                                    (3,579)       (5,973)       (10,992)      (24,013)      (23,475)
 Cash flow hedges - changes in fair value                                                                    (1,455)       217           (2,345)       (299)         (2,123)
 Cash flow hedges - reclassified to profit or loss                                                           1,494         (179)         1,614         (292)         2,623
 Total comprehensive income for the period                                                                   (4,687)       (8,655)       (20,494)      (28,003)      (44,539)

 Total comprehensive income for the period attributable to:
 - Owners of the parent                                                                                      (4,596)       (8,295)       (20,337)      (28,046)      (45,404)
 - Non-controlling interest                                                                                  (92)          (360)         (158)         43            865
                                                                                                             (4,688)       (8,655)       (20,495)      (28,003)      (44,539)

 Total comprehensive income for the period attributable to owners of the
 parent:
 - Continuing operations                                                                                     (4,596)       (7,954)       (20,337)      (27,048)      (39,777)
 - Discontinued operations*                                                                                  -             (341)         -             (998)         (5,627)
                                                                                                             (4,596)       (8,295)       (20,337)      (28,046)      (45,404)

 

 

* Total comprehensive income for the period relating to discontinued
operations for Q2 2024 includes the loss of £nil (Q2 2023: £279,000) and
foreign exchange loss of £nil (Q2 2023: £62,000). FY23 includes the loss of
£5,505,000 and foreign exchange loss of £122,000.

 

The accompanying notes are an integral part of this consolidated financial
information.

Benchmark Holdings plc

 

Consolidated Balance Sheet as at 31 March 2024

 

 

                                                                          31 March 2024  31 March 2023  30 September 2023
 All figures in £000's                                             Notes  (unaudited)    (unaudited)    (audited)
 Assets
 Property, plant and equipment                                            68,525         76,414         73,411
 Right-of-use assets                                                      16,717         22,365         19,804
 Intangible assets                                                        190,861        215,077        206,077
 Equity-accounted investees                                               4,538          3,136          3,558
 Other investments                                                        1              14             14
 Biological and agricultural assets                                       18,547         20,605         18,406
 Non-current assets                                                       299,189        337,611        321,270
 Inventories                                                              22,790         27,129         25,269
 Biological and agricultural assets                                       25,132         22,550         27,586
 Trade and other receivables                                              54,589         48,433         59,795
 Cash and cash equivalents                                                20,759         38,647         36,525
                                                                          123,270        136,759        149,175
 Assets held for sale                                              10     -              -              850
 Current assets                                                           123,270        136,759        150,025
 Total assets                                                             422,459        474,370        471,295
 Liabilities
 Trade and other payables                                                 (30,326)       (29,723)       (47,329)
 Loans and borrowings                                              11     (17,292)       (22,115)       (20,045)
 Corporation tax liability                                                (4,583)        8,413          (6,422)
 Provisions                                                               (1,843)        (1,574)        (1,280)
 Current liabilities                                                      (54,044)       (61,825)       (75,076)
 Loans and borrowings                                              11     (76,212)       (82,878)       (81,954)
 Other payables                                                           (7,986)        (6,257)        (6,842)
 Deferred tax                                                             (21,291)       (24,293)       (24,106)
 Provisions                                                               -              -              (700)
 Non-current liabilities                                                  (105,489)      (113,428)      (113,602)
 Total liabilities                                                        (159,533)      (175,253)      (188,678)
 Net assets                                                               262,926        299,117        282,617
 Issued capital and reserves attributable to owners of the parent
 Share capital                                                     12     739            739            739
 Additional paid-in share capital                                  12     37,428         37,924         37,428
 Capital redemption reserve                                               5              5              5
 Retained earnings                                                        175,344        201,962        183,489
 Hedging reserve                                                          (934)          (1,294)        (203)
 Foreign exchange reserve                                                 44,290         54,391         54,947
 Equity attributable to owners of the parent                              256,872        293,727        276,405
 Non-controlling interest                                                 6,054          5,390          6,212
 Total equity and reserves                                                262,926        299,117        282,617

 

 

 

The accompanying notes are an integral part of this consolidated financial
information.

Benchmark Holdings plc

 

Consolidated Statement of Changes in Equity for the period ended 31 March 2024

 

 

 

 

                                                      Share     Additional paid-in share capital    Other       Hedging      Retained     Total attributable       Non-          Total

capital
reserves*
reserve
 earnings
 to equity holders of
controlling
equity

parent
interest
                                                      £000      £000                                £000        £000         £000         £000                     £000          £000

 As at 1 October 2023 (audited)                      739       37,428                              54,952      (203)        183,489      276,405                  6,212         282,617
 Comprehensive income/(loss) for the period
 Profit/(loss) for the period                        -         -                                   -           -            (8,949)      (8,949)                  177           (8,772)
 Other comprehensive income/(loss)                   -         -                                   (10,657)    (731)        -            (11,388)                 (335)         (11,723)
 Total comprehensive income/(loss) for the period    -         -                                   (10,657)    (731)        (8,949)      (20,337)                 (158)         (20,495)
 Contributions by and distributions to owners
 Share-based payment                                 -         -                                   -           -            804          804                      -             804
 Total contributions by and distributions to owners  -         -                                   -           -            804          804                      -             804
 Total changes in ownership interests                -         -                                   -           -            -            -                        -             -
 Total transactions with owners of the Company       -         -                                   -           -            804          804                      -             804
 As at 31 March 2024 (unaudited)                     739       37,428                              44,295      (934)        175,344      256,872                  6,054         262,926

 As at 1 October 2022 (audited)                      704       420,824                             77,710      (703)        (185,136)    313,399                  9,886         323,285
 Comprehensive income/(loss) for the period
 Profit/(loss) for the period                        -         -                                   -           -            (4,141)      (4,141)                  742           (3,399)
 Other comprehensive income/(loss)                   -         -                                   (23,314)    (591)        -            (23,905)                 (699)         (24,604)
 Total comprehensive income/(loss) for the period    -         -                                   (23,314)    (591)        (4,141)      (28,046)                 43            (28,003)
 Contributions by and distributions to owners
 Share issue                                         35        12,985                              -           -            -            13,020                   -             13,020
 Share issue costs recognised through equity         -         (1,386)                             -           -            -            (1,386)                  -             (1,386)
 Cancellation of part of share premium account       -         (394,235)                           -           -            394,235      -                        -             -
 Share-based payment                                 -         -                                   -           -            475          475                      -             475
 Total contributions by and distributions to owners  35        (382,900)                           -           -            394,710      11,845                   -             11,845
 Changes in ownership
 Acquisition of NCI                                                                                -                        (3,470)      (3,470)                  (4,539)       (8,009)
 Total changes in ownership interests                -         -                                   -           -            (3,470)      (3,470)                  (4,539)       (8,009)
 Total transactions with owners of the Company       35        (382,900)                           -           -            391,240      8,375                    (4,539)       3,836
 As at 31 March 2023 (unaudited)                     739       37,924                              54,396      (1,294)      201,963      293,728                  5,390         299,118

 As at 1 October 2022 (audited)                      704       420,824                             77,710      (703)        (185,136)    313,399                  9,886         323,285
 Comprehensive income/(loss) for the period
 Profit/(loss) for the period                        -         -                                   -           -            (23,146)     (23,146)                 1,582         (21,564)
 Other comprehensive income/(loss)                   -         -                                   (22,758)    500          -            (22,258)                 (717)         (22,975)
 Total comprehensive income/(loss) for the period    -         -                                   (22,758)    500          (23,146)     (45,404)                 865           (44,539)
 Contributions by and distributions to owners
 Share issue                                         35        12,985                              -           -            -            13,020                   -             13,020
 Share issue costs recognised through equity         -         (2,146)                             -           -            -            (2,146)                  -             (2,146)
 Cancellation of part of share premium account       -         (394,235)                           -           -            394,235      -                        -             -
 Share-based payment                                 -         -                                   -           -            1,006        1,006                    -             1,006
 Total contributions by and distributions to owners  35        (383,396)                           -           -            395,241      11,880                   -             11,880
 Changes in ownership
 Acquisition of NCI                                  -         -                                   -           -            (3,470)      (3,470)                  (4,539)       (8,009)
 Total changes in ownership interests                -         -                                   -           -            (3,470)      (3,470)                  (4,539)       (8,009)
 Total transactions with owners of the Company       35        (383,396)                           -           -            391,771      8,410                    (4,539)       3,871
 As at 30 September 2023 (audited)                   739       37,428                              54,952      (203)        183,489      276,405                  6,212         282,617

 

*Other reserves in this statement is an aggregation of capital redemption
reserve and foreign exchange reserve.

 

Benchmark Holdings plc

 

Consolidated Statement of Cash Flows for the period ended 31 March 2024

 

 

 

 

 All figures in £000's                                                          Q2 2024       Q2 2023       YTD Q2 2024   YTD Q2 2023   FY 2023

(unaudited)
(unaudited)
(unaudited)
(unaudited)
(audited)
 Cash flows from operating activities
 Loss for the period                                                            (1,148)       (2,720)       (8,772)       (3,399)       (21,564)
 Adjustments for:
 Depreciation and impairment of property, plant and equipment                   2,098         2,215         5,067         4,248         8,453
 Depreciation and impairment of right-of-use assets                             1,220         2,336         4,500         4,918         10,260
 Amortisation and impairment of intangible fixed assets                         4,221         4,410         8,489         9,912         18,495
 (Profit)/loss on sale of property, plant and equipment                         (231)         1             (226)         (36)          (121)
 Loss on sale of discontinued operation                                         -             -             -             -             3,774
 Finance income                                                                 (76)          (292)         (286)         (320)         (2,802)
 Finance costs                                                                  2,710         2,028         5,395         1,715         10,535
 Loss on disposal of investments in joint ventures                              -             -             (42)          -             -
 Share of (profit)/loss of equity-accounted investees, net of tax               (667)         1             (985)         (55)          32
 Foreign exchange gains                                                         (1,079)       (1,365)       (334)         (1,104)       (1,814)
 Share-based payment expense                                                    552           176           804           475           1,005
 Tax expense                                                                    477           703           910           1,482         3,365
 Decrease/(increase) in trade and other receivables                             1,151         2,060         2,342         6,071         (6,570)
 Decrease in inventories                                                        1,177         946           1,747         2,517         2,877
 Decrease/(increase) in biological and agricultural assets                      (695)         (2,401)       118           893           (1,659)
 (Decrease)/Increase in trade and other payables                                (2,564)       (4,040)       (15,957)      (13,673)      3,909
 Decrease /(increase) in provisions                                             (1,010)       (4)           (1,003)       (13)          386
                                                                                6,136         4,054         1,767         13,631        28,561
 Income taxes paid                                                              (2,513)       (2,632)       (3,717)       (4,141)       (8,556)
 Net cash flows generated from operating activities                             3,623         1,422         (1,950)       9,490         20,005
 Investing activities
 Acquisition of subsidiaries                                                    -             -             -             -             (48)
 Purchase of investments in associates                                          (143)         (244)         (143)         (307)         (558)
 Receipts from disposal of subsidiaries, joint ventures, and other investments  -             -             37            -             1,250
 Purchases of property, plant and equipment                                     (849)         (1,425)       (1,770)       (3,254)       (5,953)
 Purchase of intangibles                                                        (35)          (47)          (85)          (77)          (196)
 Capitalised research and development costs                                     (32)          (143)         (94)          (197)         (632)
 Cash advances and loans made to other parties                                  -             415           -             -             -
 Proceeds from sale of fixed assets                                             253           2             271           77            227
 Cash receipts from swap contracts                                              -             -             -             -             11
 Interest received                                                              82            159           286           319           627
 Net cash flows used in investing activities                                    (724)         (1,283)       (1,498)       (3,439)       (5,272)
 Financing activities
 Proceeds of share issues                                                       -             -             -             13,020        13,020
 Share-issue costs recognised through equity                                    -             (264)         -             (1,650)       (2,146)
 Acquisition of minority interests in subsidiaries                              -             (8,009)       -             (8,009)       (8,009)
 Proceeds from bank or other borrowings, net of borrowing fees                  (259)         21,402        (259)         20,802        21,847
 Repayment of bank or other borrowings                                          (860)         (12,163)      (1,246)       (16,560)      (18,470)
 Interest and finance charges paid                                              (2,257)       (1,871)       (4,507)       (4,082)       (9,131)
 Repayments of lease liabilities                                                (2,514)       (2,489)       (5,368)       (4,689)       (9,438)
 Net cash used in financing activities                                          (5,890)       (3,394)       (11,380)      (1,168)       (12,327)
 Net increase/(decrease) in cash and cash equivalents                           (2,991)       (3,255)       (14,828)      4,883         2,406
 Cash and cash equivalents at beginning of period                               24,164        42,782        36,525        36,399        36,399
 Effect of movements in exchange rate                                           (414)         (880)         (938)         (2,635)       (2,280)
 Cash and cash equivalents at end of period                                     20,759        38,647        20,759        38,647        36,525

 

 

 

 

Benchmark Holdings plc

 

Unaudited notes to the quarterly financial statements for the period ended 31
March 2024

 

 

 

1.       Basis of preparation

 

Benchmark Holdings plc (the 'Company') is a company incorporated and domiciled
in the United Kingdom. These consolidated quarterly financial statements as at
and for the six months ended 31 March 2024 comprises those of the Company and
its subsidiaries (together referred to as the 'Group').

 

These consolidated quarterly financial statements do not comprise statutory
accounts within the meaning of section 434 of the Companies Act 2006 and are
unaudited. These financial statements do not include all the information
required for a complete set of IFRS financial statements. However, selected
explanatory notes are included to explain events and transactions that are
significant to an understanding of the changes in the Group's financial
position and performance since the last annual financial statements. The
Group's last annual statutory financial statements as at and for the year
ended 30 September 2023 were prepared in accordance with (i) UK-adopted
International Accounting Standards and (ii) IFRS adopted pursuant to
Regulation (EC) No. 1606/2002 as it applied in the European Union ("Adopted
IFRS") and are available from the Company's website at www.benchmarkplc.com
(http://www.benchmarkplc.com) .

 

The prior year comparatives are derived from audited financial information for
Benchmark Holdings PLC Group as set out in the Annual Report and Accounts for
the year ended 30 September 2023 and the unaudited financial information in
the Quarterly Financial Report for the six months ended 31 March 2023. The
comparative figures for the financial year ended 30 September 2023 are not the
Company's statutory accounts for that financial year. Those accounts were
approved by the Directors on 29 November 2023 and have been delivered to the
Registrar of Companies. The audit report received on those accounts was (i)
unqualified and (ii) did not contain a statement under section 498(2) or (3)
of the Companies Act 2006.

 

Statement of Compliance

 

These consolidated quarterly financial statements have been prepared and
approved by the Directors in accordance with UK and EU adopted IAS 34 'Interim
Financial Reporting'. These financial statements do not include all of the
information required for the full annual financial statements and should be
read in conjunction with the Group's last annual consolidated financial
statements as at and for the year ended 30 September 2023. These consolidated
quarterly financial statements were approved by the Board of Directors on 22
May 2024.

 

Going concern

 

The Group's business activities, together with the factors likely to affect
its future development, performance and position are set out in the Management
Report.

 

As at 31 March 2024 the Group had net assets of £262.9m (30 September 2023:
£282.6m), including cash of £20.8m (30 September 2023: £36.5m) as set out
in the consolidated balance sheet. The Group made a total loss for the period
of £8.8m (year ended 30 September 2023: loss £21.6m).

 

As noted in the Management Report, the business experienced tough market
conditions in the shrimp markets in FY23 which continued into the first
quarter of FY24, but robust results in the second quarter are evidence of
early signs of market recovery. Additionally, the Health and Genetics business
areas both had good quarters and the group as a whole is trading in line with
expectations for the full year.

 

The Directors have reviewed forecasts and cash flow projections for a period
of at least 12 months including downside sensitivity assumptions in relation
to trading performance across the Group to assess the impact on the Group's
trading and cash flow forecasts and on the forecast compliance with the
covenants included within the Group's financing arrangements.

 

In the downside analysis performed, the Directors considered severe but
plausible scenarios on the Group's trading and cash flow forecasts, firstly in
relation to continued roll out of the Ectosan®Vet and CleanTreat offering.
Sensitivities considered included modelling slower ramp up of the
commercialisation of Ectosan® Vet and CleanTreat® through delayed roll-out
of the revised operating model for the service, together with reduction in
medicine sales. Key downside sensitivities modelled in other areas included
assumptions on slower commercialisation of SPR shrimp, slower salmon egg sales
growth in Chile and removal of an additional financing opportunity within
Genetics, along with sensitivity of lower sales growth from a possible slower
recovery in the shrimp market in Advanced Nutrition. Mitigating measures
within the control of management have been identified should they be required
in response to these sensitivities, including reductions in areas of
discretionary spend, tight control over new hires, deferral of capital
projects and temporary hold on R&D for non-imminent products.

 

During the period on 26 March 2024 an additional facility of £7.5m was added
to the existing RCF with an expiry date of 31 March 2025. The original £20m
RCF term remains unaltered, ending on 27 June 2025. The Directors consider
that adequate finance facilities are in place, and with financial instruments
in place to fix interest rates and opportunities available to mitigate
globally high inflation rates, the Group continues to show resilience against
current global economic pressures.

 

The Board believes that the current share price materially undervalues the
combined value of Benchmark's businesses and the long-term prospects of the
Company.  Consequently, the Board announced on 22 January 2024 the decision
to undertake a formal review of the Company's strategic options, which include
a potential sale of the Company as a whole or of one or more of the individual
business units. The sales process is ongoing, but there are currently no deals
identified or underway and all parts of the business are operating as usual,
so there is no impact on the Directors' assessment of going concern.

 

The Directors are therefore confident that even under all of the above
sensitivity analysis and ongoing strategic review, the Group has sufficient
liquidity and resources throughout the period under review whilst still
maintaining adequate headroom against the borrowing covenants. They therefore
remain confident that the Group has adequate resources to continue to meet its
liabilities as and when they fall due within the period of 12 months from the
date of approval of these financial statements. Based on their assessment, the
Directors believe it remains appropriate to prepare the financial statements
on a going concern basis.

 

2.      Accounting policies

 

The accounting policies adopted are consistent with those used in preparing
the consolidated financial statements for the financial year ended 30
September 2023.

 

Taxes on income in the interim periods are accrued using the tax rate that
would be applicable to expected total earnings.

Alternative performance measures ('APMs')

The Directors measure the performance of the Group based on a range of
financial measures, including measures not recognised by UK or EU-adopted
IFRS. These APMs may not be directly comparable with other companies' APMs,
and the Directors do not intend these as a substitute for, or superior to,
IFRS measures.

Directors have presented the performance measures Adjusted EBITDA, Adjusted
Operating Profit, Adjusted Profit Before Tax and Adjusted EBITDA excluding
fair value movement on biological assets because they monitor performance at a
consolidated level using these and believe that these measures are relevant to
an understanding of the Group's financial performance (see note 13).
Furthermore, the Directors also refer to current period results using constant
currency, which are derived by retranslating current period results using the
prior year's foreign exchange rates.

Use of estimates and judgements

The preparation of quarterly financial information requires management to make
certain judgements, estimates and assumptions that affect the application of
accounting policies and the reported amounts of assets and liabilities, income
and expense. Actual amounts may differ from these estimates.

 

In preparing these quarterly financial statements the significant judgements
made by management in applying the Group's accounting policies and the key
sources of estimation uncertainty were the same as those applied to the
consolidated financial statements for the year ended 30 September 2023.

 

3.      Segment information

 

Operating segments are reported in a manner consistent with the reports made
to the chief operating decision maker. It is considered that the role of chief
operating decision maker is performed by the Board of Directors.

 

The Group operates globally and for management purposes is organised into
reportable segments based on the following business areas:

 

·      Genetics - harnesses industry leading salmon breeding
technologies combined with state-of-the-art production facilities to provide a
range of year-round high genetic merit ova.

·      Advanced Nutrition - manufactures and provides technically
advanced nutrition and health products to the global aquaculture industry.

·      Health - the segment provides health products and services to the
global aquaculture market.

 

In order to reconcile the segmental analysis to the consolidated income
statement, corporate and inter-segment sales are also shown. Corporate sales
represent revenues earned from recharging certain central costs to the
operating business areas, together with unallocated central costs.

Measurement of operating segment profit or loss

Inter-segment sales are priced along the same lines as sales to external
customers, with an appropriate discount being applied to encourage use of
Group resources at a rate acceptable to local tax authorities.  This policy
was applied consistently throughout the current and prior period.

 

3.     Segment information (continued)

 

Reconciliations of segmental information to IFRS measures

 

  Segmental Revenue
  All figures in £000's    Q2 2024       Q2 2023        YTD Q2 2024   YTD Q2 2023    FY 2023

(unaudited)
(unaudited)*
(unaudited)
(unaudited)*
(audited)*
   Genetics                13,231        13,042         28,395        34,481         65,791
   Advanced Nutrition      21,130        22,644         40,413        45,324         78,503
   Health                  5,401         8,692          11,460        19,077         25,514
   Corporate               1,349         1,436          2,698         2,873          5,747
   Inter-segment sales     (1,360)       (1,447)        (2,742)       (2,893)        (5,811)
   Total                   39,751        44,367         80,224        98,862         169,744

 

  Segmental Adjusted EBITDA
  All figures in £000's        Q2 2024       Q2 2023       YTD Q2 2024    YTD Q2 2023    FY 2023

(unaudited)
(unaudited)*
(unaudited)
(unaudited)*
(audited)*
   Genetics                   3,425         3,420          5,923         5,983          14,409
   Advanced Nutrition         5,276         6,169          9,876         11,466         18,374
   Health                     1,636         2,583          2,206         6,650          4,772
   Corporate                  (189)         (1,079)        (1,183)       (2,039)        (3,317)
   Total                      10,148        11,093         16,822        22,060         34,238

 

  Reconciliation of Reportable Segments Adjusted EBITDA to Loss before
 taxation
  All figures in £000's                                                  Q2 2024       Q2 2023       YTD Q2 2024    YTD Q2 2023    FY 2023

(unaudited)
(unaudited)*
(unaudited)
(unaudited)*
(audited)*
  Total reportable segment Adjusted EBITDA                              10,337        12,172         18,005        24,099         37,555
  Corporate Adjusted EBITDA                                             (189)         (1,079)        (1,183)       (2,039)        (3,317)
  Adjusted EBITDA                                                       10,148        11,093         16,822        22,060         34,238
  Exceptional - restructuring, acquisition and disposal related items   (1,962)       (1,716)        (2,479)       (2,688)        (7,817)
  Depreciation and impairment                                           (3,318)       (4,551)        (9,567)       (9,166)        (18,713)
  Amortisation and impairment                                           (4,221)       (4,410)        (8,489)       (9,912)        (18,495)
  Net finance costs                                                     (1,317)       (2,432)        (4,148)       (2,210)        (7,412)
  Loss before taxation                                                  (670)         (2,016)        (7,861)       (1,916)        (18,199)

 

  Reconciliation of segmental information to IFRS measures - Revenue and Loss
 before tax

  Revenue
                                                          Q2 2024        Q2 2023       YTD Q2 2024     YTD Q2 2023    FY 2023

(unaudited)
(unaudited)*
(unaudited)
(unaudited)*
(audited)
  Total revenue per segmental information                39,751         44,367         80,224         98,862         169,744
  Less: revenue from discontinued operations             -              (130)          -              (203)          (268)
  Consolidated revenue                                   39,751         44,237         80,224         98,659         169,476

  Loss before tax
                                                          Q2 2024        Q2 2023       YTD Q2 2024     YTD Q2 2023    FY 2023

(unaudited)
(unaudited)*
(unaudited)
(unaudited)*
(audited)
  Profit/(loss) before tax per segmental information     (670)          (2,016)        (7,861)        (1,916)        (18,199)
  Less: loss before tax from discontinued operations     -              279            -              732            5,505
  Consolidated Profit/(loss) before tax                  (670)          (1,737)        (7,861)        (1,184)        (12,694)

 

* Results include discontinued operations, see note 5 for further detail

4.     Revenue

 

The Group's operations and main revenue streams are those described in its
financial statements to 30 September 2023. The Group's revenue is derived from
contracts with customers.

 

Disaggregation of revenue

 

In the following tables, revenue is disaggregated by primary geographical
market and by sales of goods and services. The table includes a reconciliation
of the disaggregated revenue with the Group's reportable segments (see note
3).

 

Sale of goods and provision of services

 

                          3 months ended 31 March 2024
 All figures in £000's     Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total    Discontinued    Continuing
  Sale of goods           12,687      21,087                4,624      -            -                      38,398   -               38,398
  Provision of services   542         34                    777        -            -                      1,353    -               1,353
  Inter-segment sales     2           9                     -          1,349        (1,360)                -        -               -
                          13,231      21,130                5,401      1,349        (1,360)                39,751   -               39,751

                          3 months ended 31 March 2023
 All figures in £000's     Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total    Discontinued    Continuing
  Sale of goods           11,083      22,635                6,115      -            -                      39,833   130             39,703
  Provision of services   1,957       -                     2,577      -            -                      4,534    -               4,534
  Inter-segment sales     2           9                     -          1,436        (1,447)                -        -               -
                          13,042      22,644                8,692      1,436        (1,447)                44,367   130             44,237

                          6 months ended 31 March 2024
 All figures in £000's     Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total    Discontinued    Continuing
  Sale of goods           27,529      40,341                9,083      -            -                      76,953   -               76,953
  Provision of services   860         34                    2,377      -            -                      3,271    -               3,271
  Inter-segment sales     6           38                    -          2,698        (2,742)                -        -               -
                          28,395      40,413                11,460     2,698        (2,742)                80,224   -               80,224

                          6 months ended 31 March 2023
 All figures in £000's     Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total    Discontinued    Continuing
  Sale of goods           32,204      45,307                13,564     -            -                      91,075   203             90,872
  Provision of services   2,274       -                     5,513      -            -                      7,787    -               7,787
  Inter-segment sales     3           17                    -          2,873        (2,893)                -        -               -
                          34,481      45,324                19,077     2,873        (2,893)                98,862   203             98,659

                          12 months ended 30 September 2023
 All figures in £000's     Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total    Discontinued    Continuing
  Sale of goods           61,372      78,449                17,707     -            -                      157,528  268             157,260
  Provision of services   4,409       -                     7,807      -            -                      12,216   -               12,216
  Inter-segment sales     10          54                    -          5,747        (5,811)                -        -               -
                          65,791      78,503                25,514     5,747        (5,811)                169,744  268             169,476

 

 

4.     Revenue (continued)

 

Primary geographical markets

 

 

                         3 months ended 31 March 2024
 All figures in £000's    Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total    Discontinued    Continuing
   Norway                6,873       138                   2,348      -            -                      9,359    -               9,359
  Vietnam                -           3,071                 -          -            -                      3,071    -               3,071
   India                 -           2,572                 -          -            -                      2,572    -               2,572
  Iceland                1,478       -                     -          -            -                      1,478    -               1,478
   Ecuador               8           1,733                 -          -            -                      1,741    -               1,741
  Canada                 35          40                    2,470      -            -                      2,545    -               2,545
   Turkey                -           2,317                 -          -            -                      2,317    -               2,317
  Indonesia              66          853                   -          -            -                      919      -               919
   Faroe Islands         1,238       -                     70         -            -                      1,308    -               1,308
   Greece                -           1,711                 -          -            -                      1,711    -               1,711
  China                  92          743                   -          -            -                      835      -               835
   United Kingdom        576         19                    93         -            -                      688      -               688
   Chile                 2,009       -                     420        -            -                      2,429    -               2,429
  Rest of Europe         317         1,759                 -          -            -                      2,076    -               2,076
  Rest of World          537         6,165                 -          -            -                      6,702    -               6,702
  Inter-segment sales    2           9                     -          1,349        (1,360)                -        -               -
                         13,231      21,130                5,401      1,349        (1,360)                39,751   -               39,751

 

                         3 months ended 31 March 2023
 All figures in £000's    Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total    Discontinued    Continuing
   Norway                6,177       252                   6,157      -            -                      12,587   -               12,587
  Vietnam                -           2,330                 -          -            -                      2,330    -               2,330
   India                 -           2,822                 -          -            -                      2,822    -               2,822
  Iceland                1,184       -                     -          -            -                      1,184    -               1,184
   Ecuador               9           1,832                 -          -            -                      1,841    -               1,841
  Canada                 30          37                    2,328      -            -                      2,395    -               2,395
   Turkey                -           2,528                 -          -            -                      2,528    -               2,528
  Indonesia              130         418                   -          -            -                      548      -               548
   Faroe Islands         2,224       -                     119        -            -                      2,343    -               2,343
   Greece                -           2,002                 -          -            -                      2,002    -               2,002
  China                  152         1,155                 -          -            -                      1,307    -               1,307
   United Kingdom        814         8                     -          -            -                      822      -               822
   Chile                 1,121       9                     88         -            -                      1,218    -               1,218
  Rest of Europe         474         1,716                 -          -            -                      2,190    -               2,190
  Rest of World          725         7,526                 -          -            -                      8,250    130             8,120
  Inter-segment sales    2           9                     -          1,436        (1,447)                -        -               -
                         13,042      22,644                8,692      1,436        (1,447)                44,367   130             44,237

 

4.     Revenue (continued)

 

Primary geographical markets (continued)

 

                         6 months ended 31 March 2024
 All figures in £000's    Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total    Discontinued    Continuing
   Norway                16,430      449                   7,157      -            -                      24,036   -               24,036
  Vietnam                -           4,706                 -          -            -                      4,706    -               4,706
   India                 -           6,735                 -          -            -                      6,735    -               6,735
  Iceland                2,711       -                     -          -            -                      2,711    -               2,711
   Ecuador               40          3,222                 -          -            -                      3,262    -               3,262
  Canada                 95          62                    2,612      -            -                      2,769    -               2,769
   Turkey                9           4,215                 -          -            -                      4,224    -               4,224
  Indonesia              158         2,135                 -          -            -                      2,293    -               2,293
   Faroe Islands         2,710       -                     502        -            -                      3,212    -               3,212
   Greece                -           3,659                 -          -            -                      3,659    -               3,659
  China                  190         1,245                 -          -            -                      1,435    -               1,435
   United Kingdom        1,350       26                    146        -            -                      1,522    -               1,522
   Chile                 2,993       -                     1,043      -            -                      4,036    -               4,036
  Rest of Europe         699         3,415                 -          -            -                      4,114    -               4,114
  Rest of World          1,004       10,506                -          -            -                      11,510   -               11,510
  Inter-segment sales    6           38                    -          2,698        (2,742)                -        -               -
                         28,395      40,413                11,460     2,698        (2,742)                80,224   -               80,224

 

                         6 months ended 31 March 2023
 All figures in £000's    Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total    Discontinued    Continuing
   Norway                23,061      342                   14,452     -            -                      37,855   -               37,855
  Vietnam                -           5,025                 -          -            -                      5,025    -               5,025
   India                 -           7,025                 -          -            -                      7,025    -               7,025
  Iceland                2,972       -                     -          -            -                      2,972    -               2,972
   Ecuador               29          3,572                 -          -            -                      3,601    -               3,601
  Canada                 55          58                    3,893      -            -                      4,006    -               4,006
   Turkey                2           4,732                 -          -            -                      4,734    -               4,734
  Indonesia              338         2,109                 -          -            -                      2,447    -               2,447
   Faroe Islands         3,319       -                     348        -            -                      3,667    -               3,667
   Greece                -           4,271                 -          -            -                      4,271    -               4,271
  China                  152         2,991                 -          -            -                      3,143    -               3,143
   United Kingdom        1,551       27                    42         -            -                      1,620    -               1,620
   Chile                 1,133       11                    342        -            -                      1,486    -               1,486
  Rest of Europe         770         3,338                 -          -            -                      4,108    -               4,108
  Rest of World          1,096       11,806                -          -            -                      12,902   203             12,699
  Inter-segment sales    3           17                    -          2,873        (2,893)                -        -               -
 -                       34,481      45,324                19,077     2,873        (2,893)                98,862   203             98,659

 

4.     Revenue (continued)

 

Primary geographical markets (continued)

 

                         12 months ended 30 September 2023
 All figures in £000's    Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total    Discontinued    Continuing
   Norway                39,008      899                   19,596     -            -                      59,503   -               59,503
  Vietnam                -           11,087                -          -            -                      11,087   -               11,087
   India                 -           9,743                 -          -            -                      9,743    -               9,743
  Iceland                7,343       -                     -          -            -                      7,343    -               7,343
   Ecuador               38          7,257                 -          -            -                      7,295    -               7,295
  Canada                 3,071       96                    4,032      -            -                      7,199    -               7,199
   Turkey                93          7,009                 -          -            -                      7,102    -               7,102
  Indonesia              637         4,099                 -          -            -                      4,736    -               4,736
   Faroe Islands         6,160       -                     718        -            -                      6,878    -               6,878
   Greece                -           6,759                 -          -            -                      6,759    -               6,759
  China                  327         4,502                 -          -            -                      4,829    -               4,829
   United Kingdom        3,957       85                    177        -            -                      4,219    -               4,219
   Chile                 1,824       12                    991        -            -                      2,827    -               2,827
  Rest of Europe         1,470       4,879                 -          -            -                      6,349    -               6,349
  Rest of World          1,853       22,022                -          -            -                      23,875   268             23,607
  Inter-segment sales    10          54                    -          5,747        (5,811)                -        -               -
                         65,791      78,503                25,514     5,747        (5,811)                169,744  268             169,476

 

 

5.     Discontinued activities

During FY23, the group divested its tilapia business for consideration of USD
1 in a management buy out. Consequently, these operations were classified as
discontinued in the prior year and a restatement of the consolidated income
statement for the period ended 31 March 2024 has been made to reflect these
changes.

 

Summary of restatement of Q2 FY23 results as reported in Q2 FY24 financial
statements

 

                                            Continuing operations         Discontinued operations
 All figures in £000's                      Revenue      Adjusted EBITDA  Loss from continuing operations  Loss from discontinued operations
 As stated in Q2 FY23 financial statements  98,862       22,060           (3,399)                          -
 Reclassified in Q1                         (73)         368              453                              (453)
 Reclassified in Q2                         (130)        194              279                              (279)
 As stated in Q2 FY24 financial statements  98,659       22,622           (2,667)                          (732)

 

 

Results from discontinued operations

                                                            Q2 FY24  Q2 FY23  YTD Q2 FY24  YTD Q2 FY23  FY23
                                                            £000     £000     £000         £000         £000
 Revenue                                                    -        130      -            203          268
 Cost of sales                                              -        (236)    -            (480)        (973)
 Gross profit                                               -        (106)    -            (277)        (705)
 Research and development costs                             -        (1)      -            (13)         (59)
 Other operating costs                                      -        (87)     -            (272)        (490)
 Share of profit of equity-accounted investees, net of tax  -        -        -            -            -
 Adjusted EBITDA                                            -        (194)    -            (562)        (1,254)
 Exceptional loss on disposal                               -        -        -            -            (3,913)
 EBITDA                                                     -        (194)    -            (562)        (5,167)
 Depreciation and impairment                                -        (76)     -            (152)        (304)
 Amortisation and impairment                                -        -        -            -            -
 Operating loss / Loss before taxation                      -        (270)    -            (714)        (5,471)
 Net finance costs                                          -        (9)      -            (18)         (34)
 Loss before taxation                                       -        (279)    -            (732)        (5,505)
 Tax on loss                                                -        -        -            -            -
 Loss from discontinued operations                          -        (279)    -            (732)        (5,505)

 

Exceptional items within discontinued operations

 

 

                                            Q2 FY24  Q2 FY23  YTD Q2 FY24  YTD Q2 FY23  FY23
                                            £000     £000     £000         £000         £000

 Profit/(loss) on disposal of subsidiaries  -        -        -            -            3,774
 Profit/(loss) on other asset disposals     -        -        -            -            139
 Total exceptional recognised               -        -        -            -            3,913

 

 

Results from discontinued operations by segment

The results from discontinued operations relate solely to the Genetics
operating segment.

 

 

6.     Exceptional items from continuing operations -
restructuring/acquisition and disposal related items

 

Items that are material because of their size or nature, are non-recurring and
whose significance is sufficient to warrant separate disclosure and
identification within the consolidated financial statements are referred to as
exceptional items. The separate reporting of exceptional items helps to
provide an understanding of the Group's underlying performance.

 

 

 All figures in £000's                Q2 2024       Q2 2023       YTD Q2 2024   YTD Q2 2023   FY 2023

(unaudited)
(unaudited)
(unaudited)
(unaudited)
(audited)
  Acquisition related items           -             -                           -             652
  Exceptional restructuring costs     2,139         1,716         2,656         2,688         3,470
  Disposal related items              (177)         -             (177)         -             (218)
 Total exceptional items              1,962         1,716         2,479         2,688         3,904

 

Exceptional restructuring costs in the quarter include £1,782,000 (Q2 2023:
£nil) relating to the formal review of the Company's strategic options and
potential sale of all or parts of the group, and other restructuring costs of
£357,000 (Q2 2023: £50,000).  In the year to date, the costs of the
strategic review were £1,782,000 (YTD Q2 2023: £nil; FY 2023: £nil) and
other restructuring costs were £357,000 (YTD Q2 2023: £135,000; FY 2023:
£872,000). Additionally in the prior year, exceptional restructuring costs
were incurred on legal and professional expenses in relation to preparing for
listing the Group on the Oslo stock exchange, and these were £1,666,000 in Q2
2023 (YTD Q2 2023: £2,553,000; FY 2023: £2,598,000).

 

Disposal related items is a gain of £177,000 from sale of equipment left over
from an old business disposed of in a prior year.  In FY23 there was a credit
of £235,000 for additional contingent consideration received relating to the
disposal of a subsidiary in a prior year, which was offset by £17,000 of
other disposal related costs.

 

In FY23 acquisition related items comprise fees incurred in the year in
connection with an aborted acquisition.

 

7.     Net finance costs from continuing operations

 

 

 All figures in £000's                                                 Q2 2024       Q2 2023       YTD Q2 2024   YTD Q2 2023   FY 2023

(unaudited)
Restated
(unaudited)
Restated
(audited)

(unaudited)
(unaudited)
 Interest received on bank deposits                                    76            163           286           323           627
 Foreign exchange gains on financing activities                        -             -             -             -             158
 Foreign exchange gains on operating activities                        1,808         499           2,063         5,169         4,709
 Cash flow hedges - ineffective portion of changes in fair value       -             129           -             2,651         2,176
 Finance income                                                        1,884         791           2,349         8,143         7,670
 Leases (interest portion)                                             (353)         (527)         (689)         (873)         (1,620)
 Foreign exchange losses on operating activities                       (491)         (1,195)       (1,102)       (5,961)       (4,547)
 Interest expense on financial liabilities measured at amortised cost  (2,357)       (1,491)       (4,706)       (3,501)       (8,881)
 Finance costs                                                         (3,201)       (3,214)       (6,497)       (10,335)      (15,048)
 Net finance costs recognised in profit or loss                        (1,317)       (2,423)       (4,148)       (2,192)       (7,378)

 

 

 

 

8.     Taxation

 

 All figures in £000's                                     Q2 2024       Q2 2023       YTD Q2 2024   YTD Q2 2023   FY 2023

(unaudited)
(unaudited)
(unaudited)
(unaudited)
(audited)

 Analysis of charge in period
 Current tax:
 Current income tax expense on profits for the period      1,307         997           2,626         2,835         6,178
 Adjustment in respect of prior periods                    -             -             -             -             (880)
 Total current tax charge                                  1,307         997           2,626         2,835         5,298

 Deferred tax:
 Origination and reversal of temporary differences         (830)         (293)         (1,716)       (1,352)       (1,933)
 Total deferred tax charge/(credit)                        (830)         (293)         (1,716)       (1,352)       (1,933)
                                                                                                     -             -
 Total tax charge                                          477           704           910           1,483         3,365

 

 

 

9.     Loss per share

 

Basic loss per share is calculated by dividing the loss attributable to
ordinary equity holders of the Company by the weighted average number of
ordinary shares in issue during the period.

 

                                                            Q2 2024       Q2 2023       YTD Q2 2024   YTD Q2 2023   FY 2023

(unaudited)
Restated
(unaudited)
Restated
(audited)

(unaudited)
(unaudited)
 Loss attributable to equity holders of the parent (£000)
 Continuing operations                                      (1,321)       (2,579)       (8,948)       (3,409)       (17,641)
 Discontinued operations                                    -             (279)         -             (732)         (5,505)
 Total                                                      (1,321)       (2,858)       (8,948)       (4,141)       (23,146)

 Weighted average number of shares in issue (thousands)     739,464       723,173       739,480       724,505       731,935

 Basic loss per share (pence)
 Continuing operations                                      (0.18)        (0.36)        (1.21)        (0.47)        (2.41)
 Discontinued operations                                    -             (0.04)        -             (0.10)        (0.75)
 Total                                                      (0.18)        (0.40)        (1.21)        (0.57)        (3.16)

 

Diluted loss per share is calculated by adjusting the weighted average number
of ordinary shares outstanding to assume conversion of all dilutive potential
ordinary shares. This is done by calculating the number of shares that could
have been acquired at fair value (determined as the average market price of
the Company's shares for the period) based on the monetary value of the
subscription rights attached to outstanding share options and warrants. The
number of shares calculated above is compared with the number of shares that
would have been issued assuming the exercise of the share options and
warrants.

 

Therefore, the Company is required to adjust the earnings per share
calculation in relation to the share options that are in issue under the
Company's share-based incentive schemes, and outstanding warrants. However, as
any potential ordinary shares would be anti-dilutive due to losses being made
there is no difference between Basic loss per share and Diluted loss per share
for any of the periods being reported.

 

A total of 14,056,643 potential ordinary shares have not been included within
the calculation of statutory diluted loss per share for the year (30 September
2023: 8,948,132 and 31 March 2023: 4,312,880). These potential ordinary shares
could dilute earnings/loss per share in the future.

10.   Assets held for sale

 

During 2022, management committed to sell certain property, plant and
equipment held within the Health business area. The property concerned is no
longer required by the business and the decision was made to sell. The market
value of the property fell during the period and a further impairment charge
of £200,000 has been incurred to write the asset down to its current market
value of £300,000 (30 September 2023: £850,000). The property was sold for
£300,000 on 28 March 2024.

 

There were no liabilities directly associated with the assets held for sale.

 

 Assets held for sale               YTD Q2 2024   YTD Q2 2023   FY 2023

(unaudited)
(unaudited)
(audited)
 All figures in £000's
 Property, plant and equipment      -             -             850
 Total Assets held for sale         -             -             850

 

 

11. Loans and borrowings

 

                               YTD Q2 2024   YTD Q2 2023   FY 2023

(unaudited)
(unaudited)
(audited)
 All figures in £000's
 Non-Current
 2025 750m NOK Loan notes      54,914        56,756        57,604
 Bank borrowings               14,808        16,974        16,799
 Unamortised debt issue costs  (373)         -             (742)
 Lease liabilities             6,863         9,148         8,293
                               76,212        82,878        81,954
 Current
 Bank borrowings               9,257         9,421         9,320
 Unamortised debt issue costs  (1,048)       -             (842)
 Lease liabilities             9,083         12,694        11,567
                               17,292        22,115        20,045
 Total loans and borrowings    93,504        104,993       101,999

 

 

The Group has an unsecured floating rate listed green bond of NOK 750m in
issue. The bond which matures in September 2025, has a coupon of three-month
NIBOR + 6.50% p.a. with quarterly interest payments, and is listed on the Oslo
Stock Exchange.

 

The Group has a secured GBP 20m RCF provided by DNB Bank ASA, maturing on 27
June 2025. This facility was extended on the same terms in March 2024 by GBP
7.5m, to a total facility of GBP 27.5m, with the GBP 7.5m extension maturing
on 27 March 2025. The margin on this combined facility is a minimum of 2.75%
and a maximum of 3.25%, dependent upon the leverage of the Group above the
relevant risk-free reference or IBOR rates depending on which currency is
drawn. As at 31 March 2024 there was £19.75m undrawn.

 

Additionally, Benchmark Genetics Salten AS had the following loans (which are
ring-fenced debt without recourse to the remainder of the Group) at 31 March
2024:

 

•      term loan with Nordea Bank with a balance of NOK 164.3m, which
has a maturity date of five years ending 15 January 2028 and an interest rate
of 2.5% above three-month NIBOR.

•      twelve month working capital facility of NOK 20.0m provided by
Nordea Bank Norge Abp. This was undrawn at 31 March 2024

•      term loan with a balance of NOK 33.2m provided by Innovasjon
Norge. The loan is a 12-and-a-half year term loan maturing in March 2031. The
interest rate on this loan at 31 March 2024 was 7.45%

•      an additional 15-year term loan with a balance of NOK 9.7m
provided by Innovasjon Norge and maturing in July 2038. The interest rate on
this loan at 31 March 2024 was 6.6%

•      a loan of NOK 15.5m provided by the minority shareholder Salten
Stamfisk AS. The loan attracts interest at 2.5% above three month NIBOR and is
repayable on maturity of the Nordea loan above.

12.   Share capital and additional paid-in share capital

 

                                               Number       Share Capital  Additional paid-in

share capital
 Allotted, called up and fully paid                         £000           £000
 Ordinary shares of 0.1 pence each
 Balance at 30 September 2023                  739,352,390  739            37,428
 Exercise of share options                     199,580      -              -
 Shares issued through placing and open offer  34,576       -              -
 Balance at 31 March 2024                      739,586,546  739            37,428

 

 

13.   Alternative performance measures and other metrics

 

Management has presented the performance measures EBITDA, Adjusted EBITDA,
Adjusted EBITDA before fair value movement in biological assets, Adjusted
Operating Profit and Adjusted Profit Before Tax because it monitors
performance at a consolidated level using these and believes that these
measures are relevant to an understanding of the Group's financial
performance.

 

Adjusted EBITDA which reflects underlying profitability, is earnings before
interest, tax, depreciation, amortisation, impairment, and exceptional items
and is shown on the Income Statement.

 

Adjusted EBITDA before fair value movements in biological assets, which is
Adjusted EBITDA before the non-cash fair value movements in biological assets
arising from their revaluation in line with International Accounting
Standards.

 

Adjusted Operating Profit is operating loss before exceptional items and
amortisation and impairment of intangible assets excluding development costs
as reconciled below.

 

Adjusted Profit Before Tax is earnings before tax, amortisation and impairment
of intangibles assets excluding development costs, and exceptional items as
reconciled below. These measures are not defined performance measures in IFRS.
The Group's definition of these measures may not be comparable with similarly
titled performance measures and disclosures by other entities.

 

13.    Alternative performance measures and other metrics (continued)

 

Reconciliation of Adjusted Operating Profit/(loss) to Operating Profit/(loss)

 

 All figures in £000's                                                             Q2 2024       Q2 2023       YTD Q2 2024   YTD Q2 2023   FY 2023

(unaudited)
Restated
(unaudited)
Restated
(audited)

(unaudited)
(unaudited)
 Revenue                                                                           39,751        44,237        80,224        98,659        169,476
 Cost of sales                                                                     (18,866)      (19,313)      (40,976)      (49,337)      (82,726)
 Gross profit                                                                      20,885        24,924        39,248        49,322        86,750
 Research and development costs                                                    (1,542)       (1,434)       (3,059)       (2,985)       (6,069)
 Other operating costs                                                             (9,862)       (12,203)      (20,352)      (23,771)      (45,157)
 Depreciation and impairment                                                       (3,318)       (4,475)       (9,567)       (9,014)       (18,409)
 Amortisation of capitalised development costs                                     (604)         (610)         (1,211)       (1,227)       (2,437)
 Share of profit/(loss) of equity accounted investees net of tax                   667           -             985           56            (32)
 Adjusted operating profit                                                         6,226         6,202         6,044         12,381        14,646
 Exceptional - restructuring, acquisition and disposal related items               (1,962)       (1,716)       (2,479)       (2,688)       (3,904)
 Amortisation and impairment of intangible assets excluding development costs      (3,617)       (3,800)       (7,278)       (8,685)       (16,058)
 Operating profit/(loss)                                                           647           686           (3,713)       1,008         (5,316)

 

Reconciliation of Loss Before Taxation to Adjusted Profit Before Tax

 

 All figures in £000's                                                             Q2 2024       Q2 2023       YTD Q2 2024   YTD Q2 2023   FY 2023

(unaudited)
Restated
(unaudited)
Restated
(audited)

(unaudited)
(unaudited)

 Loss before taxation                                                              (670)         (1,737)       (7,861)       (1,184)       (12,694)
 Exceptional - restructuring, acquisition and disposal related items               1,962         1,716         2,479         2,688         3,904
 Amortisation and impairment of intangible assets excluding development costs      3,617         3,800         7,278         8,685         16,058
 Adjusted profit before tax                                                        4,909         3,779         1,896         10,189        7,268

 

Other Metrics

 

 All figures in £000's                                                   Q2 2024       Q2 2023       YTD Q2 2024   YTD Q2 2023    FY 2023

(unaudited)
Restated
(unaudited)
Restated
(audited)

(unaudited)
(unaudited)
 Total R&D Investment
 Research and development costs
 - Continuing operations                                                 1,542         1,434         3,059         2,985          6,069
 - Discontinued operations                                               -             1             -             13             59
 Internal capitalised development costs                                  32            144           94            197            632
 Total R&D investment                                                    1,574         1,579         3,153         3,195          6,760

 All figures in £000's                                                    Q2 2024       Q2 2023      YTD Q2 2024    YTD Q2 2023    FY 2023

(unaudited)
Restated
(unaudited)
Restated
(audited)

(unaudited)
(unaudited)
 Adjusted EBITDA excluding fair value movement in biological assets
 Adjusted EBITDA                                                         10,148        11,287        16,822        22,622         35,492
 Exclude fair value movement                                             (287)         (1,401)       506           (247)          103
 Adjusted EBITDA excluding fair value movement in biological assets      9,861         9,886         17,328        22,375         35,595

13.  Alternative performance measures and other metrics (continued)

 

Liquidity

 

A key financial covenant is a minimum liquidity of £10m, defined as cash plus
undrawn facilities.

 

 All figures in £000's         Q2 2024       Q2 2023       FY 2023

(unaudited)
(unaudited)
(audited)
 Cash and cash equivalents    20,759        38,647        36,525
 Undrawn bank facility        19,750        12,110        12,250
 Total liquidity              40,509        50,757        48,775

 

 

The undrawn bank facility relates to the RCF facility.  At 31 March 2024,
£7.75m of the RCF was drawn (31 March 2023: £7.89m, 30 September 2023:
£7.75m), leaving £19.75m undrawn (31 March 2023: £12.11m, 30 September
2023: £12.25m).

 

 

14.   Net debt

Net debt is cash and cash equivalents less loans and borrowings.

                                                                     31 March 2024  31 March 2023  30 September 2023
 All figures in £000's                                               (unaudited)    (unaudited)    (audited)
 Cash and cash equivalents                                           20,759         38,647         36,525
 Loans and borrowings (excluding lease liabilities) - current        (8,209)        (9,421)        (8,478)
 Loans and borrowings (excluding lease liabilities) - non-current    (69,349)       (73,730)       (73,661)
 Net debt excluding lease liabilities                                (56,799)       (44,504)       (45,614)
 Lease liabilities - current                                         (9,083)        (12,694)       (11,567)
 Lease liabilities - non-current                                     (6,863)        (9,148)        (8,293)
 Net debt                                                            (72,745)       (66,346)       (65,474)

 

 

We hereby confirm that the financial statements for the period from 1 October
2023 to 31 March 2024, to the best of our knowledge, have been prepared in
accordance with IAS 34 - Interim Financial Reporting - and that the
information in the accounts gives a true and fair view of the Group and of the
Group's assets, liabilities, financial position and overall results.

We also confirm that, to the best of our knowledge, the half-year report gives
a true and fair view of the main events during the accounting period and their
effect on the accounts for the second half year, as well as the principal
risks and uncertainties, described below (which have remained unchanged from
those disclosed in the Company Annual Report of FY23), facing the Company and
the Group in the next accounting period.

This Statement was approved by the board of directors and signed on its behalf
by:

 

 Trond Williksen

 (Chief Executive Officer)

 Date: 22 May 2024

 

 

 

 

Principal risks and uncertainties

The Group's principal risks are categorised as either strategic, operational,
financial or emerging risks and are developed through the Audit Committee and
Board's review of the Group's risk register, performance of our businesses and
analysis of emerging global trends.

Strategic risks

 Risks                                               Risk commentary                                                                  Risk mitigation and controls                                                     Business Areas affected
 Competition and loss of competitive advantage       ·      Falling behind competitors with the development and                       ·      Innovative development focus and strong pipeline of products.             Advanced Nutrition, Health and Genetics
                                                     commercialisation of new, innovative products.

                                                                                ·      Intellectual Property ("IP") protection including patents.
                                                     ·      Threat to market share and revenues.

                                                                                ·      Strong customer relationships with key account structure.

 Reliance on continued success of existing products  ·      The Group is currently exposed                                            ·      Increasing number of products/ services from development pipeline         Advanced Nutrition, Health and Genetics

to risk by limited diversity of revenue streams.                                is diversifying revenues.

                                                     ·      Risks associated with legal costs of protecting Group IP.                 ·      Strong Group legal team with dedicated IP expertise.

                                                     ·      Group products require the holding of certain licences,                   ·      Vigorous defence of own IP.
                                                     accreditations or regulatory approvals that could be withdrawn.

                                                                                ·      High levels of employee competency and stringent processes
                                                     ·      Failure to gain additional claims on the labels for certain Group         related to
                                                     products which could result in reduced revenue from such products.
regulatory affairs.

                                                     ·      Failure to achieve the projected                                          ·      Highly proficient and experienced

                                                     customers growth/uptake for newly                                                commercial team equipped with

                                                     launched products                                                                extensive knowledge and with robust

                                                                                                                                      customer relationships.
 Delivery of cross-Group synergies                   ·      Risks associated with failure to fully realise operational                ·      EMT continues tracking progress of the Group strategy on a weekly         Advanced Nutrition, Health and Genetics
                                                     synergies and cost benefits.                                                     basis.

                                                     ·      Lower profitability and cash generation, and slower returns than          ·      Extended-EMT assists with planning and managing
                                                     anticipated.
key projects.

                                                     ·      Risks on delivering the synergy within the timeline set.

 New product                                         ·      Risk that pipeline products may                                           ·      Close dialogue with regulators.                                           Advanced Nutrition, Health and Genetics

and service commercialisation
be delayed or fail technically

before launch.                                                                  ·      The innovation board (which includes the head of Group

                                                                                Innovation) monitors the R&D projects across the Group.
                                                     ·      Risk inherent in timing and market penetration of new products

and services.                                                                   ·      Experienced Group regulatory affairs team, commercial team and
                                                                                                                                      Marketing team.

                                                                                                                                      ·      Close dialogue with customers regarding their product and service
                                                                                                                                      satisfaction to enable efficient and appropriate reaction to their feedback
                                                                                                                                      and needs.

 

 

Operational risks

 Risks                                                                           Risk commentary                                                                 Risk mitigation and controls                                                     Business Areas affected
 Environmental risk and crisis management                                        ·      The nature of certain of the Group's operating activities exposes        ·      We have implemented standards and requirements which govern key           Advanced Nutrition, Health and Genetics
                                                                                 us to certain significant risks to the environment, such as incidents           risk management activities such as inspection, maintenance, testing, business
                                                                                 associated with releases of chemicals or hazardous substances when conducting   continuity and crisis response.
                                                                                 our operations, which could result in liability, fines, risk to our product
                                                                                 permissions and reputational damage.

                                                                                 ·      There is a risk that natural disasters could lead to damage to
                                                                                 infrastructure, loss of resources, products or containment of hazardous
                                                                                 substances.

                                                                                 ·      Our business activities could be disrupted if we do not respond,
                                                                                 or are perceived not to respond, in an appropriate manner to any major crisis
                                                                                 or if we are not able to restore or replace critical operational capacity.
 Biological and climatic risks                                                   ·      The Group is exposed to the risk of disease within the Group's           ·      The Group operates the highest levels of biosecurity.                     Advanced Nutrition, Health and Genetics
                                                                                 own operations and disease in the market resulting in possible border

                                                                                 closures.                                                                       ·      The Group holds genetic stock at multiple sites; increasingly

                                                                               sources from its own land-based salmon breeding facilities.
                                                                                 ·      Sales of the Group's sea lice medicines and other relevant

                                                                                 solutions such as CleanTreat® are affected by the degree of sea lice            ·      The Group operates containment zones which mitigates the risk of
                                                                                 challenge in the environment, which is driven by sea temperatures and other     border closures affecting its ability to import or export.
                                                                                 biological factors.

                                                                                                                                                                 ·      The Group has placed increased focus on insuring its biological
                                                                                                                                                                 stock.

                                                                                                                                                                 ·      The Group's product diversity across business areas offers some
                                                                                                                                                                 mitigation.
 Volatility of end markets (salmon, sea bass and shrimp markets) and market and  ·      Market fluctuations in shrimp production volumes and pricing,            ·      The geographic diversity of the business area's customer base             Advanced Nutrition, Health and Genetics
 regulatory trends                                                               often influenced by disease, drive customer and food services demand for        offers some mitigation.
                                                                                 shrimp.

                                                                               ·      The Group's product diversity across business areas offers some
                                                                                 ·      Market and regulatory trends for tackling sea lice have an               mitigation.
                                                                                 influence on customer demand for the Group's sea lice products.

 Threats to the supply chain                                                     ·   Benchmark is reliant on a small number of key raw materials and             ·   Dual supplies of raw materials where possible.                               Advanced Nutrition, Genetics, Health
                                                                                 manufacturers and suppliers for important products.

                                                                               ·   Supplies secured with contractual arrangements, and import
                                                                                 ·   The Group has R&D and production sites which are important to its           authorisations in the process of being applied for where deemed material for
                                                                                 current revenues and future success and which are leased.                       the Group.

                                                                                 ·   Commissioning of new facilities could be delayed leading to late            ·   Seek long-term tenure of sites.
                                                                                 product deliveries.

                                                                                 ·   Benchmark relies on third parties for importation authorisations
                                                                                 required in certain jurisdictions for certain products.
 Health and well-being of employees                                              ·   Poor health or well-being impacts employees' lives and reduces              ·   Well-developed health and safety management regime in place across the       Advanced Nutrition, Genetics, Health
                                                                                 productivity.                                                                   Group.

                                                                                 ·   Some aquaculture activities have inherent operational risks.                ·   Senior level commitment to ESG programme Group-wide.
 Recruitment and retention of high-calibre people                                ·   To maintain market leadership, it is essential that the Group has and       ·   Centralised people team delivering people strategy.                          Advanced Nutrition, Genetics, Health
                                                                                 keeps people with key skills.

                                                                                                                                                                 ·   Succession planning process.

                                                                                                                                                                 ·   Remuneration policy designed to encourage retention.
 Loss of key IT system                                                           ·   The Group IT systems facilitate daily work, collaboration and hold          ·   Internal experienced IT team.                                                Advanced Nutrition, Genetics, Health
                                                                                 Group IP and trade secrets.

                                                                               ·   Increasing integration of software platforms to improve security and
                                                                                 ·   Multiple risks of systems failure or cyber attack.                          reliability.

                                                                                 ·   Loss of access or key information would be disruptive to the Group.         ·   The Group increased the frequency of phishing simulation exercises to
                                                                                                                                                                 ensure staff awareness of cyber security.
 Geopolitical risk                                                               ·   The diverse locations of our operations around the world expose us to a     ·   We seek to manage this risk through development and maintenance of           Advanced Nutrition, Genetics, Health
                                                                                 wide range of political developments and consequent changes to the economic     relationships with governments and stakeholders. We closely monitor events and
                                                                                 and operating environment. Geopolitical risk is inherent to many regions in     implement risk mitigation plans where appropriate.
                                                                                 which we operate, and heightened political or social tensions or changes in
                                                                                 key relationships could adversely affect the Group.
 Application of appropriate standards of governance                              ·   As an international business, the Group is required to comply with laws     ·   Experienced Group legal, finance, people, regulatory affairs, investor       Advanced Nutrition, Genetics, Health
                                                                                 and regulations in several jurisdictions.                                       relations, health and safety and IT teams work closely with the business

                                                                               areas.
                                                                                 ·   There is risk of non-compliance leading to potential fines, penalties,

                                                                                 loss of revenues and damage to reputation.                                      ·   Training programme, whistleblowing policy, and informal routes by which
                                                                                                                                                                 concerns can be raised, are designed to identify and address potential
                                                                                                                                                                 non-compliance.

 

 

 

Financial and legal risks

 Risks                                                              Risk                                                                            Risk mitigation                                                                  Business Areas affected

commentary
and controls
 Maintain liquidity and manage leverage                             ·      Failure to identify and maintain sufficient liquidity headroom.          ·      Close control of cash flows with regular update of short- and             Advanced Nutrition, Genetics, Health

                                                                               long-term projections.
                                                                    ·      Risk to funding of key growth strategies.

                                                                                                                                                    ·      The refinanced facilities provide greater covenant flexibility
                                                                                                                                                    and headroom.

                                                                                                                                                    ·      Group Treasury Manager oversees cash flow management.

                                                                                                                                                    ·      Group treasury policy introduced to support how the Group manages
                                                                                                                                                    cash.
 Growth in trading results in higher investment in working capital  ·      Top-line growth through new products and markets can drive               ·      Business area management of pricing and credit terms.                     Advanced Nutrition, Genetics, Health
                                                                    changing patterns of working capital.

                                                                               ·      Close monitoring of investment in working capital by the EMT and
                                                                    ·      Growth in some markets presents increased risk of slow paying or         Plc Board.
                                                                    bad debts.

                                                                                                                                                    ·      Key performance indicators include working capital measures.
 Currency exchange                                                  ·      The Group as a whole is also exposed to fluctuations in currency         ·      The Group reduces its exposure to its principal foreign currency          Advanced Nutrition, Genetics, Health
                                                                    exchange rates. These impact sales volumes where products are priced by         risks through the use of hedging instruments.
                                                                    reference to USD but sold in local currencies; and impacts reported results

                                                                    when local results, assets and liabilities are converted to GBP for reporting   ·      Group treasury policy explains how the Group should manage FX
                                                                    purposes.                                                                       risk.
 Criminal activity, fraud, bribery and compliance risk              ·      Some countries where the Group operates may be exposed to high           ·      The Group provides compliance training programmes to all its              Advanced Nutrition, Genetics, Health
                                                                    levels of risk relating to criminal activity, fraud, bribery and corruption.    employees through an online training platform and provide face-to-face and

                                                                               virtual training to higher risk teams.
                                                                    ·      There are a number of regulatory requirements applicable to the

                                                                    Group and its listing on the London and Oslo Stock exchanges.                   ·      The Group has introduced a code of conduct for its suppliers.

                                                                                                                                                    ·      The CFO and Group Legal Counsel are involved in mitigating
                                                                                                                                                    fraudulent activities in the Group.

                                                                                                                                                    ·      The Group has access to competent

                                                                                                                                                    and experienced external counsel.

                                                                                                                                                    ·      Fraud response policy introduced.

 

 

Emerging risks

 

 Risks                                                  Risk                                                                             Risk mitigation                                                                  Business Areas affected

commentary
and controls
 Climate change                                         ·      Climate change and the evolving regulatory environment may expose         ·      The Group's Sustainability Committee reports to the Board                 Advanced Nutrition, Genetics, Health
                                                        the Group to regulatory breaches, significant disruption, reputational risk or   regularly and its mandate is to ensure the Group's strategy and operations are
                                                        a reduction in supply for biological raw materials, and demand for products or   carried out within the framework of caring for the environment, people, and
                                                        services.                                                                        animals. Its work aligns with major frameworks including the London Stock
                                                                                                                                         Exchange Guidance for Environmental, Social and Governance reporting and the
                                                                                                                                         UN Sustainable Development Goals.

                                                                                                                                         ·      New ESG strategy approved and implemented by the Group.

                                                                                                                                         ·      Plan adopted for reduction in the Group's carbon emissions and
                                                                                                                                         progressing according to timetable set.

                                                                                                                                         ·      The Group is exploring alternatives

                                                                                                                                         solutions to decrease its reliance

                                                                                                                                         on raw materials that could be

                                                                                                                                         vulnerable to the impacts of climate

                                                                                                                                         changes.
 Environmental, Social and Governance responsibilities  ·      Increasingly our stakeholders are requiring reassurance that we           ·      Code of Conduct in place.                                                 Advanced Nutrition, Genetics, Health
                                                        are overseeing and responding to ethical and environmental issues across the

                                                        Group's business.                                                                ·      New ESG strategy approved and in place.

                                                                                                                                         ·      Plan adopted for reduction in the Group's carbon emissions.

                                                                                                                                         ·      Code of conduct and ABC policies in place.

                                                                                                                                         ·      Green bond successfully launched and subscribed.

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IR SESESFELSELI

Recent news on Benchmark Holdings

See all news